Global Enzymatic Wound Debridement Market: A Sophisticated Way to Promote Healing

Global Enzymatic Wound Debridement Market

Debridement is the process of softening or liquefying and removing devitalized tissue and is an important component of efficient wound care. They create the wound bed for healing. The main function of the debridement is to remove the infected tissue from a wound so that healthy tissues can be exposed. Enzymatic debridement is an extremely selective wound debridement technique that utilizes naturally produced proteolytic enzymes developed specifically by the pharmaceutical and healthcare industries to eliminate degenerated tissue. Either with other techniques such as surgical debridement or alone, this enzymatic debridement is used to readily remove the toxic tissue. They are usually used to remove the destructive tissues from chronic lesions such as burns, trauma wounds, infected wounds and others.  It is important to remove this dead skin because they stop the formation of new tissues.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-enzymatic-wound-debridement-market

Some of the factors responsible for the growth of this market are as follows:

  • Rising number of accidents related to burn injuries: Burn is one of the most common injuries which can damage the skin and can also kills the affected skin cells. If immediate care is not given this can cause death or other complications. As per the damage caused to the skin, the burn is divided into three degrees first, second and third. The main factors of the burns are excessive sun exposure, electrical burns, scalding from hot water, fire and chemical burns. Some of this burn such as chemical and electrical needs instant medical attention as they have the ability to damage the internal part of the body as well
  • Growing medical tourism sector: Today, people are travelling from one country to another so they can get better medical facilities and care so they can treat their disease more efficiently. Due to the high quality of healthcare, affordability, access to care and improved convenience, patients are travelling. There are also medical tourism facilitators who help the patient to manage their visit to another country for medical care. People do travel to other country for treatment because of the factors such as cheaper cost of the treatment, unavailability of treatment in their country, ineffective results and others

The global enzymatic wound debridement market is segmented on the basis of type as chronic wound, and acute wound; product as collagenase product, papain product, and others and end- user as hospitals, homecare and others

Few of the launches and acquisition by some prominent player in the market are as follow:

  • In August 2018, B. Braun Medical Inc announced the launch of their Prontosan Wound Gel X. Gel X is a viscous wound gel with betaine and polyhexanide to withstand microbial colonization in the dressing and softens necrotic tissue to facilitate autolytic debrides. It is an efficient microbial barrier for cleaning and moisturizing wound beds. They can be used on diabetic foot, first and second degree burns, large surface area wounds and others
  • In July 2018, Mölnlycke announced the acquisition of SastoMed GmbH so they can expand their wound healing processes and can treat chronic wounds. This acquisition will help the company to add two innovative products such as Granudacyn and Granulox to their product portfolio. This will help the company to strengthen them in both active and passive wound healing

“According to Data Bridge Market Research, global enzymatic wound debridement market is set to witness a substantial CAGR of 5.95% in the forecast period of 2019- 2026”

Few of the major competitors currently working in the global enzymatic wound debridement market are Smith & Nephew, ConvaTec Group PLC, PAUL HARTMANN Limited, Coloplast, Integra LifeSciences Corporation, Medline Industries, Inc, B. Braun Melsungen AG, RLS Global., Phoenix Eagle, Solsys Medical, Mölnlycke Health Care AB, DeRoyal Industries, Inc. and others

Wounds do not cure faster in diabetic patients and often reach the infection or even gangrene phase. In such instances, pus causing infection is regarded to be removed from wound debridement. Increasing numbers of surgical procedures such as orthopedic, cancer, heart, and other significant processes sometimes leave profound cuts and injuries that may not cure more quickly. Doctors take wound debridement into account in such instances. They have the ability to remove the dead tissues so they can prevent the infection from spreading and help the new tissue to expose. This is the factor which is creating new opportunities for this market.